Full text is available at the source.
Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity
Effects of Single and Dual Glucagon-Like Peptide-1 Treatments on Inflammatory Bowel Disease in People with Obesity
AI simplified
Abstract
Use of semaglutide is associated with a reduced risk of IBD-related surgery (HR 0.33, CI 0.13-0.83).
- No significant differences in all-cause hospitalization, IBD-hospitalization, or pancreatitis were observed between GLP-1 users and non-users.
- Among 89 patients using tirzepatide, none required IBD-related surgery, compared to 2 matched controls.
- Black patients using GLP-1 therapy had an increased risk of all-cause hospitalizations (HR 1.59, CI 1.11-2.29), but not IBD-related hospitalization or surgery.
- Serum CRP levels were significantly reduced with GLP-1 use.
- Overall, GLP-1-based therapies were well tolerated among obese patients with inflammatory bowel disease.
AI simplified